Document is current
Any future updates will be listed below
-
Authors
Glass, Charity C.
Pride, Robert M.
Freedman, Rachel A.
Mayer, Erica L.
Ogayo, Esther R.
Chavez-MacGregor, Mariana
King, Tari A.
Mittendorf, Elizabeth A.
Kantor, Olga
-
Funding
Funding for this research was provided by:
Pamela and Nick Gelsomini Breast Surgical Oncology Fellowship Fund
Rob and Karen Hale Distinguished Chair in Surgical Oncology
- License Information
-
More Information
Article History
Received: 7 June 2023
Accepted: 8 August 2023
First Online: 5 September 2023
Disclosures
: Elizabeth A. Mittendorf reports compensated service on scientific advisory boards for AstraZeneca, BioNTech and Merck; uncompensated service on steering committees for Bristol Myers Squibb and Roche/Genentech; speaker’s honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche/Genentech (via an SU2C grant) and Gilead. She also reports research funding from Susan Komen for the Cure, for which she serves as a Scientific Advisor, as well as uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. Tari A. King reports speaker honoraria and an advisory board role for Exact Sciences. Erica L. Mayer reports consulting for Lilly, Novartis, AstraZeneca, Gilead, and Diaccurate. Mariana Chavez-MacGregor reports consulting for Lilly, Novartis, AstraZeneca, Exact Sciences, and Genentech. Charity C. Glass, Robert M. Pride, Rachel A. Freedman, Esther R. Ogayo, and Olga Kantor report no disclosures.
